Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors.
Anticancer Agents Med Chem
; 23(15): 1702-1709, 2023.
Article
em En
| MEDLINE
| ID: mdl-37231721
ABSTRACT
Cardiotoxicity represents an important acute or chronic adverse event of treatment modalities for childhood cancer. In the last two decades the emergence of novel cancer therapies has aimed to increase unaided or mostly in combination with conventional chemotherapy for the survival rates of pediatric cancer especially for those patients with relapsed and/or refractory disease. The use of emerging targeted therapies in combination with conventional chemotherapy is related to cardiovascular adverse events mostly reported in adults. The aim of our short review was to investigate the cardiotoxic side effects of targeted chemotherapeutic agents as monoclonal antibodies and small molecules in pediatric cancer patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Hematológicas
/
Neoplasias
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Grécia